The Pritzker School of Medicine is the M.D.-granting unit of the Biological Sciences Division of the University of Chicago. It is located on the university's main campus in the historic Hyde Park neighborhood of Chicago and matriculated its first class in 1927.

During the past decade, University of Chicago Pritzker School of Medicine conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Chicago Pritzker School of Medicine" #1 sponsor was "NYU Langone Health" with 2 trials, followed by "American Gastroenterological Association" with 1 trials sponsored, "Celgene" with 1 trials sponsored, "Eli Lilly and Company" with 1 trials sponsored and "Yale University" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Chicago Pritzker School of Medicine" #1 collaborator was "National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)" with 2 trials as a collaborator, "Office of Research on Women's Health (ORWH)" with 2 trials as a collaborator, "Loxo Oncology, Inc." with 1 trials as a collaborator, "Loyola University Chicago" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "University of Chicago Pritzker School of Medicine" are "Systemic Lupus Erythematosus" (2 trials), "Any Solid Tumor" (1 trials), "Cholangiocarcinoma" (1 trials), "Chondrosarcoma" (1 trials) and "Clostridium Difficile Infection" (1 trials). Many other conditions were trialed in "University of Chicago Pritzker School of Medicine" in a lesser frequency.

Most popular intervention types in "University of Chicago Pritzker School of Medicine" are "Drug" (4 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cisplatin" (1 trials), "Durvalumab" (1 trials), "Gemcitabine" (1 trials), "LY3410738" (1 trials) and "MRZ 0.5 mg/m^2" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of Chicago Pritzker School of Medicine" are 4 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "University of Chicago Pritzker School of Medicine". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in University of Chicago Pritzker School of Medicine, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in University of Chicago Pritzker School of Medicine, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".